respiratory syncytial virus fusion inhibitors back-up programme (ReViral)

N/A

Report date: 2025/01/26 16:57:55
NME

Base Information

Drug Namerespiratory syncytial virus fusion inhibitors back-up programme (ReViral)
Drug Alias NameRSV Fusion Inhibitors (ReViral)respiratory syncytial virus fusion inhibitors back-up programme (Pfizer)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRespiratory syncytial virus F protein inhibitors
TargetsRespiratory syncytial virus F protein
Therapy Area/IndicationsRespiratory Syncytial Virus Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesReviral Ltd
China Registration ClassN/A

Develop Information

Active CompaniesPfizer Inc
Inactive CompaniesReviral Ltd
Active IndicationsRespiratory Syncytial Virus Infections
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A